HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 84.1%

Neg 84.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.